Genzyme, Sanofi boards to meet on Sunday: sources (Reuters)
BOSTON (Reuters) – The boards of Genzyme Corp and Sanofi-Aventis SA are regular to foregather on Sunday to handle Sanofi's planned acquisition of Genzyme, according to quaternary sources with noesis of the situation.
The deal is due to be priced at $74 in cash, and allow a force value right, or CVR, with an intrinsic value of $5 to $6 a share, according to two sources with noesis of the talks.
The minimal value of the CVR is due to be between $12 and $15, to be paid out over a time punctuation of heptad or octad years, according to digit source.
An commendation has not still been finalized as Sanofi is still conducting a analyse of Genzyme's business, and an commendation may not be finalized until sometime incoming week, digit maker said.
(Reporting by Toni Clarke and Jessica Hall; Editing by saint Cooney)
Source
0 comments:
Post a Comment